Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 65343E207 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
ADAR1 Capital Management, LLC
13G
|
15.8% |
8/14/2026
Event 7/31/2026
|
||
| ADAR1 Capital Management, LLC | 15.8% | |||
| Daniel Schneeberger | 15.8% | |||
|
Ikarian Capital, LLC
13G/A
|
10.0% |
8/14/2026
Event 6/30/2026
|
||
| Ikarian Capital, LLC | 10.0% | |||
| Neil Shahrestani | 10.0% | |||
|
Simcere Zaiming, Inc.
13G/A
|
9.4% |
5/6/2026
Event 12/31/2025
|
||
| Simcere Zaiming, Inc. | 9.4% | |||
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | 9.4% | |||
| Simcere Zaiming Pharmaceutical Co., Ltd. | 9.4% | |||
| Simcere Pharmaceutical Group Limited | 9.4% | |||
| Ren Jinsheng | 9.4% | |||
| Tang Renhong | 9.4% | |||
|
Adage Capital Management, L.P.
13G
|
7.7% |
8/12/2026
Event 6/30/2026
|
||
| Adage Capital Management, L.P. | 7.7% | |||
| Robert Atchinson | 7.7% | |||
| Phillip Gross | 7.7% | |||
|
Sofinnova Venture Partners IX, L.P.
13D/A
|
7.1% |
3/5/2026
Event 12/19/2025
|
||
| Sofinnova Venture Partners IX, L.P. ("SVP IX") | 7.1% | |||
| Sofinnova Management IX, L.L.C. ("SM IX") | 7.1% | |||
| Dr. James I. Healy ("Healy") | 7.1% | |||
|
Affinity Asset Advisors, LLC
13G/A
|
6.4% |
8/13/2026
Event 6/30/2026
|
||
| Affinity Asset Advisors, LLC | 6.4% | |||
| Michael Cho | 6.4% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
SilverArc Capital Management, LLC
13G/A
|
4.9% |
5/13/2026
Event 3/31/2026
|
||
| SilverArc Capital Management, LLC | 4.9% | |||
| Devesh Gandhi | 4.9% | |||
|
Squadron Capital Management LLC
13G/A
|
1.6% |
8/14/2026
Event 6/30/2026
|
||
| Squadron Master Fund LP | 1.6% | |||
| Squadron Capital Management LLC | 1.6% | |||
| Matthew Sesterhenn | 1.6% | |||
| William Blank | 1.6% | |||